Novartis AG (BUE:NVS) Short-Term Capital Lease Obligation : ARS189,563 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Novartis AG Short-Term Capital Lease Obligation?

Novartis AG's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ARS189,563 Mil.

Novartis AG's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 (ARS73,490 Mil) to Dec. 2023 (ARS83,030 Mil) and increased from Dec. 2023 (ARS83,030 Mil) to Mar. 2024 (ARS189,563 Mil).

Novartis AG's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (ARS27,772 Mil) to Dec. 2022 (ARS42,080 Mil) and increased from Dec. 2022 (ARS42,080 Mil) to Dec. 2023 (ARS83,030 Mil).

Novartis AG Short-Term Capital Lease Obligation Historical Data

The historical data trend for Novartis AG's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Short-Term Capital Lease Obligation Chart

Novartis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

14,704.31

23,274.68

27,772.25

42,080.15

83,030.00

Novartis AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															49,585.05	59,280.00	73,489.50	83,030.00	189,562.50

Novartis AG Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Novartis AG Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Novartis AG's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Novartis AG (BUE:NVS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (BUE:NVS) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NVSEF:USA NVS:USA NVS N:Mexico NOVNz:UK 0QLR:UK NOTA:Germany NOVNEE:Switzerland NOVN:Switzerland N1VS34:Brazil

Address

Lichtstrasse 35, Basel, CHE, 4056

Website

https://www.novartis.com

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.